In the area of reduced sample sizes, instruments have become more sensitive over the years, and detector technology has improved.
As a result, users have been able to generate the same information with smaller sample sizes. Techniques for sample preparation
have improved as well, enabling purer samples to be attained. In addition, sample preparation has become largely automated.
These developments together brought greater repeatability and more-precise results.
References
1. S.King, "The Evolving Pharmaceutical Value Chain: Forecasting Growth for Small and Large Molecules," Pharm. Technol.
30 Technology Outlook: APIs, Intermediates, and Formulation suppl. s6–s10 (2006).
2. D.A. Kessler, Presentation at the Food and Drug Law Institute Annual Meeting, Washington, DC, Dec. 10, 1996,
http://www.fda.gov/speeches/kessler.html (accessed May 29, 2007).
3. P.Van Arnum, "The Changing Fortunes of APIs," Pharm. Technol.
31 (1), 52–58 (2007).
4. M.J. Akers, S.L. Nail, and M.J. Groves, "Top 10 Current Technical Issues in Parenteral Science Revisited, 1997," Pharm. Technol.
21 (7), 126–134 (1997).
5. "Thimerosal in Vaccines,"
http://www.fda.gov/ (accessed June 6, 2007).
6. M. Rios, "Bringing Formulations to Size: Strategies for Micro- and Nanoparticle Development," Pharm. Technol.
28 (11), 40–53 (2004).
|
